Published in Gastroenterology on September 20, 2008
Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology (2009) 4.82
Evolving challenges in hepatic fibrosis. Nat Rev Gastroenterol Hepatol (2010) 3.30
Pathology of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol (2010) 2.25
Advances in pediatric nonalcoholic fatty liver disease. Hepatology (2009) 2.03
Feasibility study and control values of transient elastography in healthy children. Eur J Pediatr (2011) 1.80
Noninvasive evaluation of NAFLD. Nat Rev Gastroenterol Hepatol (2013) 1.49
Nonalcoholic steatohepatitis in children: a multicenter clinicopathological study. Hepatology (2009) 1.37
Invasive and non-invasive diagnosis of cirrhosis and portal hypertension. World J Gastroenterol (2014) 1.20
Molecular serum markers of liver fibrosis. Biomark Insights (2012) 1.20
Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis. BMC Gastroenterol (2010) 1.19
Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease. J Hepatol (2013) 1.12
The evaluation of hepatic fibrosis scores in children with nonalcoholic fatty liver disease. Dig Dis Sci (2014) 1.07
Noninvasive parameters and hepatic fibrosis scores in children with nonalcoholic fatty liver disease. World J Gastroenterol (2012) 1.06
The human hyaluronan synthase 2 (HAS2) gene and its natural antisense RNA exhibit coordinated expression in the renal proximal tubular epithelial cell. J Biol Chem (2011) 1.05
Can NASH be diagnosed, graded, and staged noninvasively? Clin Liver Dis (2012) 1.05
Noninvasive biomarkers in non-alcoholic fatty liver disease: current status and a glimpse of the future. World J Gastroenterol (2014) 1.04
Acoustic radiation force impulse (ARFI) elastography for the noninvasive diagnosis of liver fibrosis in children. Pediatr Radiol (2012) 1.03
Non-invasive assessment of liver fibrosis in chronic liver diseases: implementation in clinical practice and decisional algorithms. World J Gastroenterol (2009) 1.02
Mechanisms and biomarkers of apoptosis in liver disease and fibrosis. Int J Hepatol (2012) 1.02
Pediatric nonalcoholic fatty liver disease: A clinical and laboratory challenge. World J Hepatol (2010) 1.01
Non-invasive diagnosis of advanced fibrosis and cirrhosis. World J Gastroenterol (2014) 1.00
Liver biopsy in modern clinical practice: a pediatric point-of-view. Adv Anat Pathol (2012) 0.98
Nonalcoholic fatty liver disease as a comorbidity of childhood obesity. Ped Health (2009) 0.96
Acoustic radiation force impulse imaging-normal values of liver stiffness in healthy children. Pediatr Radiol (2012) 0.96
Circulating CO3-610, a degradation product of collagen III, closely reflects liver collagen and portal pressure in rats with fibrosis. Fibrogenesis Tissue Repair (2011) 0.94
The neo-epitope specific PRO-C3 ELISA measures true formation of type III collagen associated with liver and muscle parameters. Am J Transl Res (2013) 0.93
A Guide to Non-Alcoholic Fatty Liver Disease in Childhood and Adolescence. Int J Mol Sci (2016) 0.87
The performance of enhanced liver fibrosis (ELF) test for the staging of liver fibrosis: a meta-analysis. PLoS One (2014) 0.87
Rapid progression of NASH in childhood. J Pediatr Gastroenterol Nutr (2010) 0.87
Tissue inhibitor of metalloproteinase 1 (TIMP-1) deficiency exacerbates carbon tetrachloride-induced liver injury and fibrosis in mice: involvement of hepatocyte STAT3 in TIMP-1 production. Cell Biosci (2011) 0.85
Fatty liver disease in children: eat now pay later. Hepatol Int (2010) 0.85
Biopsy-controlled liver fibrosis staging using the enhanced liver fibrosis (ELF) score compared to transient elastography. PLoS One (2012) 0.82
Performance of Enhanced Liver Fibrosis test and comparison with transient elastography in the identification of liver fibrosis in patients with chronic hepatitis B infection. J Viral Hepat (2013) 0.81
Liver fibrosis in non-alcoholic fatty liver disease - diagnostic challenge with prognostic significance. World J Gastroenterol (2015) 0.81
Noninvasive Assessment of Fibrosis in Patients with Nonalcoholic Fatty Liver Disease. Int J Endocrinol (2015) 0.80
Transient elastography for assessment of fibrosis in paediatric liver disease. Pediatr Radiol (2011) 0.80
Biomarkers in nonalcoholic fatty liver disease-the emperor has no clothes? World J Gastroenterol (2015) 0.78
Use of non-invasive parameters of non-alcoholic steatohepatitis and liver fibrosis in daily practice--an exploratory case-control study. PLoS One (2014) 0.78
Biomarkers in nonalcoholic fatty liver disease: a new era in diagnosis and staging of disease in children. J Pediatr Gastroenterol Nutr (2010) 0.78
Is juvenile liver biopsy unsafe? Putting an end to a common misapprehension. Pediatr Radiol (2009) 0.77
Noninvasive diagnosis of pediatric nonalcoholic fatty liver disease. Korean J Pediatr (2013) 0.76
Significance of liver biopsy for the evaluation of methotrexate-induced liver damage in patients with rheumatoid arthritis. Int J Clin Exp Pathol (2015) 0.76
Comparison of circulating endothelial cell/platelet count ratio to aspartate transaminase/platelet ratio index for identifying patients with cirrhosis. J Clin Exp Hepatol (2012) 0.75
Dual-photon microscopy-based quantitation of fibrosis-related parameters (q-FP) to model disease progression in steatohepatitis. Hepatology (2017) 0.75
Improvement of BMI after Lifestyle Intervention Is Associated with Normalisation of Elevated ELF Score and Liver Stiffness in Obese Children. Biomed Res Int (2015) 0.75
Isolated Hepatitis B Core Antibody Status Is Not Associated With Accelerated Liver Disease Progression in HIV/Hepatitis C Coinfection. J Acquir Immune Defic Syndr (2016) 0.75
Evaluation of Transient Elastography, Acoustic Radiation Force Impulse Imaging (ARFI), and Enhanced Liver Function (ELF) Score for Detection of Fibrosis in Morbidly Obese Patients. PLoS One (2015) 0.75
Association of HIV, Hepatitis C Virus, and Liver Fibrosis Severity With the Enhanced Liver Fibrosis Score. J Infect Dis (2015) 0.75
Current Modalities of Fibrosis Assessment in Non-alcoholic Fatty Liver Disease. J Clin Transl Hepatol (2017) 0.75
Utility of the ELF Test for Detecting Steatohepatitis in Morbid Obese Patients with Suspicion of Nonalcoholic Fatty Liver Disease. Obes Surg (2017) 0.75
The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature (2007) 7.82
Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology (2004) 6.14
Acute viral hepatitis increases liver stiffness values measured by transient elastography. Hepatology (2008) 5.77
Elastography, spleen size, and platelet count identify portal hypertension in patients with compensated cirrhosis. Gastroenterology (2012) 3.86
Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology (2008) 3.60
Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol (2006) 3.59
Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis. Hepatology (2007) 3.39
Liver stiffness is influenced by a standardized meal in patients with chronic hepatitis C virus at different stages of fibrotic evolution. Hepatology (2013) 3.06
Measurement of spleen stiffness to evaluate portal hypertension and the presence of esophageal varices in patients with HCV-related cirrhosis. Gastroenterology (2012) 2.83
Biopsy and non-invasive methods for the diagnosis of liver fibrosis: does it take two to tango? Gut (2010) 2.70
Now there are many (stages) where before there was one: In search of a pathophysiological classification of cirrhosis. Hepatology (2010) 2.68
Angiogenesis in liver disease. J Hepatol (2008) 2.31
Keratin 19: a key role player in the invasion of human hepatocellular carcinomas. Gut (2013) 2.10
StellaTUM: current consensus and discussion on pancreatic stellate cell research. Gut (2011) 2.07
NAFLD in children: a prospective clinical-pathological study and effect of lifestyle advice. Hepatology (2006) 2.06
gp120 modulates the biology of human hepatic stellate cells: a link between HIV infection and liver fibrogenesis. Gut (2009) 2.06
Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. Hepatology (2008) 2.02
Predicted effects of treatment for HCV infection vary among European countries. Gastroenterology (2012) 1.89
Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts. Am J Pathol (2009) 1.87
A secreted form of ADAM9 promotes carcinoma invasion through tumor-stromal interactions. Cancer Res (2005) 1.87
Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component. N Engl J Med (2015) 1.84
Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells. Hepatology (2005) 1.81
Analysis of clonotype distribution and persistence for an influenza virus-specific CD8+ T cell response. Immunity (2003) 1.74
Maternal drug use is a preeminent risk factor for mother-to-child hepatitis C virus transmission: results from a multicenter study of 1372 mother-infant pairs. J Infect Dis (2002) 1.68
Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis. Hepatology (2008) 1.66
The chemokine CCL21 modulates lymphocyte recruitment and fibrosis in chronic hepatitis C. Gastroenterology (2003) 1.64
Beyond scoring: a modern interpretation of disease progression in chronic liver disease. Gut (2013) 1.63
Genotype-phenotype correlation in Italian children with Wilson's disease. J Hepatol (2008) 1.63
Elastography for the non-invasive assessment of liver disease: limitations and future developments. Gut (2009) 1.60
Myofibroblast - like cells and liver fibrogenesis: Emerging concepts in a rapidly moving scenario. Mol Aspects Med (2007) 1.59
MARCKS actin-binding capacity mediates actin filament assembly during mitosis in human hepatic stellate cells. Am J Physiol Cell Physiol (2012) 1.58
Intrauterine growth retardation, insulin resistance, and nonalcoholic fatty liver disease in children. Diabetes Care (2007) 1.58
Role of a cirrhosis risk score for the early prediction of fibrosis progression in hepatitis C patients with minimal liver disease. J Hepatol (2010) 1.57
Cardiovascular effects of canrenone in patients with preascitic cirrhosis. Hepatology (2002) 1.55
Long-term course of chronic hepatitis C in children: from viral clearance to end-stage liver disease. Gastroenterology (2008) 1.52
KCNJ11 activating mutations in Italian patients with permanent neonatal diabetes. Hum Mutat (2005) 1.47
Evaluation of the aspartate aminotransferase/platelet ratio index and enhanced liver fibrosis tests to detect significant fibrosis due to chronic hepatitis C. J Clin Gastroenterol (2014) 1.44
Non invasive evaluation of portal hypertension using transient elastography. J Hepatol (2011) 1.42
Technology Insight: noninvasive assessment of liver fibrosis by biochemical scores and elastography. Nat Clin Pract Gastroenterol Hepatol (2008) 1.38
Teaching critical appraisal skills in healthcare settings. Cochrane Database Syst Rev (2011) 1.37
Exposure to bacterial cell wall products triggers an inflammatory phenotype in hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol (2005) 1.33
Proangiogenic cytokines as hypoxia-dependent factors stimulating migration of human hepatic stellate cells. Am J Pathol (2007) 1.33
Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice. Gastroenterology (2004) 1.30
Correlation of serum TNF-alpha levels and histologic liver injury scores in pediatric nonalcoholic fatty liver disease. Am J Clin Pathol (2007) 1.28
Transcriptional profiling reveals novel markers of liver fibrogenesis: gremlin and insulin-like growth factor-binding proteins. J Biol Chem (2006) 1.25
Binding of hepatitis C virus envelope protein E2 to CD81 up-regulates matrix metalloproteinase-2 in human hepatic stellate cells. J Biol Chem (2004) 1.24
Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay. Hepatology (2008) 1.24
Hepatitis C virus-replicating hepatocytes induce fibrogenic activation of hepatic stellate cells. Gastroenterology (2005) 1.24
Prevention of severe toxic liver injury and oxidative stress in MCP-1-deficient mice. J Hepatol (2006) 1.24
Evaluation of an ultrasensitive p24 antigen assay as a potential alternative to human immunodeficiency virus type 1 RNA viral load assay in resource-limited settings. J Clin Microbiol (2005) 1.21
Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease. Blood (2010) 1.21
Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis. BMC Gastroenterol (2010) 1.19
Portal hypertension secondary to myelofibrosis: a study of three cases. Am J Gastroenterol (2005) 1.18
Association between laminin-8 and glial tumor grade, recurrence, and patient survival. Cancer (2004) 1.18
Non-invasive assessment of liver fibrosis: are we ready? Lancet (2010) 1.17
4-Hydroxynonenal as a selective pro-fibrogenic stimulus for activated human hepatic stellate cells. J Hepatol (2004) 1.14
Resistin as an intrahepatic cytokine: overexpression during chronic injury and induction of proinflammatory actions in hepatic stellate cells. Am J Pathol (2006) 1.14
Anti-fibrotic therapy: lost in translation? J Hepatol (2012) 1.12
Metformin use in children with nonalcoholic fatty liver disease: an open-label, 24-month, observational pilot study. Clin Ther (2008) 1.11
Silybin, a component of sylimarin, exerts anti-inflammatory and anti-fibrogenic effects on human hepatic stellate cells. J Hepatol (2009) 1.10
Fibrosis and cirrhosis reversibility: clinical features and implications. Clin Liver Dis (2008) 1.08
Activation of p38(MAPK) mediates the angiostatic effect of the chemokine receptor CXCR3-B. Int J Biochem Cell Biol (2008) 1.07
Antifibrogenic effects of canrenone, an antialdosteronic drug, on human hepatic stellate cells. Gastroenterology (2003) 1.07
Up-regulated expression of fractalkine and its receptor CX3CR1 during liver injury in humans. J Hepatol (2002) 1.07
Adenosine monophosphate-activated protein kinase modulates the activated phenotype of hepatic stellate cells. Hepatology (2008) 1.06
A combination of the pediatric NAFLD fibrosis index and enhanced liver fibrosis test identifies children with fibrosis. Clin Gastroenterol Hepatol (2010) 1.05
Serum transaminases in children with Wilson's disease. J Pediatr Gastroenterol Nutr (2004) 1.04
Thiazolidinedione treatment inhibits bile duct proliferation and fibrosis in a rat model of chronic cholestasis. World J Gastroenterol (2005) 1.04
Liver fibrosis: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL). Hepatol Int (2008) 1.04
Expression of transmembrane 4 superfamily (TM4SF) proteins and their role in hepatic stellate cell motility and wound healing migration. J Hepatol (2002) 1.04
Long-term albumin infusion improves survival in patients with cirrhosis and ascites: an unblinded randomized trial. World J Gastroenterol (2006) 1.03
Non invasive evaluation of liver fibrosis in paediatric patients with nonalcoholic steatohepatitis. World J Gastroenterol (2006) 1.03
Hyaluronic acid predicts hepatic fibrosis in children with nonalcoholic fatty liver disease. Transl Res (2010) 1.02
IFN-gamma production by innate immune cells is sufficient for development of hypersensitivity pneumonitis. Eur J Immunol (2005) 1.01
Leptin, free leptin index, insulin resistance and liver fibrosis in children with non-alcoholic fatty liver disease. Eur J Endocrinol (2006) 1.01
Hepatic wound repair. Fibrogenesis Tissue Repair (2009) 1.01
Chemokine production during hypersensitivity pneumonitis. Eur J Immunol (2004) 1.00
Gallstone disease in the elderly: are older patients managed differently? Surg Endosc (2010) 0.99
Increased risk of hepatocellular carcinoma and liver cirrhosis in vinyl chloride workers: synergistic effect of occupational exposure with alcohol intake. Environ Health Perspect (2004) 0.99
Intracellular reactive oxygen species are required for directional migration of resident and bone marrow-derived hepatic pro-fibrogenic cells. J Hepatol (2010) 0.98
Retinol-binding protein 4: a promising circulating marker of liver damage in pediatric nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol (2009) 0.98
Performance of Doppler ultrasound in the prediction of severe portal hypertension in hepatitis C virus-related chronic liver disease. Liver Int (2007) 0.98
Combined paediatric NAFLD fibrosis index and transient elastography to predict clinically significant fibrosis in children with fatty liver disease. Liver Int (2012) 0.96
Non-invasive assessment of fibrosis in non-alcoholic fatty liver disease. Ann Hepatol (2009) 0.96